Database Query Results : Bacopa monnieri, ,

BM, Bacopa monnieri: Click to Expand ⟱
Features:

Bacopa monnieri — a medicinal botanical herb, also called Brahmi, typically used as a standardized oral extract enriched in bacosides, which are dammarane-type triterpenoid saponins. Its formal classification is a phytotherapeutic botanical / dietary supplement rather than an approved anticancer drug. Standard abbreviation: BM. The source is the aerial herb of Bacopa monnieri, a traditional Ayurvedic plant. Mechanistically, BM is best supported as a neurocognitive and cytoprotective adaptogenic extract; its anticancer activity is real but remains preclinical, heterogeneous, and often driven by isolated fractions or bacopasides rather than routine oral human exposure.

Primary mechanisms (ranked):

  1. Modulation of intrinsic apoptosis and cell-cycle arrest in cancer models
  2. Aquaporin-1 linked antitumor effects of bacopaside fractions, including reduced proliferation, migration, and angiogenic behavior
  3. Anti-inflammatory signaling with suppression of NF-κB-linked survival programs
  4. Context-dependent modulation of PI3K/AKT and MAPK stress-survival signaling
  5. Redox modulation: antioxidant / NRF2-linked cytoprotection in normal tissues, but possible pro-apoptotic oxidative stress at higher in-vitro tumor doses

Bioavailability / PK relevance: Oral BM extracts are usually standardized to bacosides, but bacosides have limited aqueous solubility and modest systemic exposure; in-vivo metabolism to aglycones / downstream metabolites likely matters. This creates a delivery constraint for oncology because many direct tumor effects are reported at micromolar in-vitro concentrations or with enriched fractions not clearly achievable after routine oral supplementation.

In-vitro vs systemic exposure relevance: Common anticancer in-vitro concentrations likely exceed typical oral systemic exposure. By contrast, cognition-related effects appear compatible with chronic low-level oral exposure and adaptive signaling over weeks rather than acute high plasma peaks.

Clinical evidence status: Small human RCT evidence exists for cognition / stress-related outcomes. Dementia / AD evidence remains inconclusive and low-certainty. Oncology evidence is preclinical only; there is no established clinical anticancer role.

Key Active Compounds
  Bacosides (especially bacoside A and B)
  Brahmin
  Hersaponin
  Betulinic acid
  Steroidal saponins

AD Pathways:
  ↓ Aβ accumulation
  ↓ Tau hyperphosphorylation
  ↓ Pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6)
  ↑ Acetylcholine levels	Inhibits AChE,
  Strong antioxidant activity	↓ ROS, ↑ SOD, ↑ catalase, and ↑ GSH levels.

Potential Anticancer Mechanisms
  Reduces oxidative stress
  Inhibits NF-κB and COX-2
  Anti-angiogenic
whole-extract Bacopa monnieri effects from purified bacopaside I / II mechanisms; this distinction matters because the more specific anticancer mechanisms are often fraction-specific.

Bacopa monnieri mechanistic pathway map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Intrinsic apoptosis and cell-cycle control ↑ apoptosis; ↓ proliferation; G0/G1 or G2/M arrest (model-dependent) ↔ / cytoprotective R/G Tumor growth restraint Most reproducible cancer-facing effect across BM fractions and bacopasides; strength depends strongly on extract composition and concentration.
2 Aquaporin-1 axis ↓ proliferation; ↓ migration; ↓ invasion / angiogenic behavior ↔ R/G Membrane transport-linked antitumor effect This is one of the more specific mechanistic signals for bacopaside I / II, especially in colorectal and endothelial models; relevance is fraction-specific rather than clearly whole-extract universal.
3 NF-κB inflammatory survival signaling ↓ ↓ R/G Anti-inflammatory and anti-survival shift Likely contributes more confidently to normal-tissue neuroprotection than to a clinically useful direct anticancer effect.
4 PI3K/AKT and MAPK stress-survival signaling ↓ AKT; ERK/JNK/p38 modulation (context-dependent) ↔ / adaptive R/G Reduced survival signaling Reported in several models, but not yet a defining or standardized BM hallmark across tumor systems.
5 Mitochondrial ROS increase and apoptotic stress ↑ ROS (high concentration only); ↑ mitochondrial apoptosis ↓ oxidative injury P/R Redox bifurcation Important duality: normal tissues trend antioxidant, while some tumor models show pro-apoptotic oxidative stress only at higher exposures.
6 NRF2-linked antioxidant defense ↔ / ↑ (context-dependent) ↑ R/G Cytoprotection Central for neuroprotection and normal-cell antioxidant effects; in cancer this could be neutral or potentially counter-therapeutic depending on context, so it is not ranked as a core anticancer mechanism.
7 Angiogenesis and endothelial remodeling ↓ ↔ G Reduced vascular support Evidence is tied mainly to AQP1-active bacopaside work and endothelial assays rather than robust human translational data.
8 HIF-1α hypoxia adaptation ↓ (model-dependent) ↔ G Reduced hypoxic adaptation Secondary / contextual axis with limited direct evidence compared with apoptosis and AQP1-linked effects.
9 Chemosensitization or radiosensitization ↔ (insufficient evidence) ↔ G Not established No convincing clinical translation yet for use as a cancer sensitizer.
10 Clinical Translation Constraint ↓ ↓ — Exposure and standardization limitation Main constraints are extract heterogeneity, fraction-specific mechanisms, uncertain human tumor exposure, and lack of oncology trials.

TSF legend: P: 0–30 min
R: 30 min–3 hr
G: >3 hr



Bacopa monnieri (BM; Brahmi) — standardized extracts (typically 20–55% bacosides) studied in cognitive aging, MCI, and stress-related impairment. Mechanistically a neuroprotective adaptogen with antioxidant, anti-inflammatory, and synaptic plasticity–modulating effects.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (↑ NRF2-linked antioxidant enzymes; ↓ lipid peroxidation)
2) ↓ Neuroinflammation (↓ NF-κB; ↓ TNF-α / IL-1β in models)
3) ↑ Synaptic plasticity signaling (↑ BDNF/CREB; dendritic spine density in models)
4) ↓ Aβ aggregation / toxicity (preclinical emphasis)
5) Cholinergic modulation (↑ acetylcholine tone; acetylcholinesterase modulation)

Bioavailability / PK relevance: Orally bioavailable extracts cross the BBB at low concentrations; chronic dosing appears necessary for measurable cognitive benefit (weeks). Plasma levels modest; effects likely cumulative/adaptive rather than acute pharmacologic spikes.

Clinical evidence status: Multiple small RCTs show modest improvements in memory acquisition and processing speed in older adults and MCI; not disease-modifying approval for AD.

Bacopa monnieri — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 ROS / Oxidative stress ↓ P/R Reduced neuronal oxidative burden Consistent antioxidant activity; decreases lipid peroxidation and improves endogenous antioxidant enzyme activity.
2 NRF2 axis ↑ R/G Stress-defense gene upregulation Supports increased SOD, catalase, glutathione enzymes; central to neuroprotection.
3 Neuroinflammation (NF-κB, cytokines) ↓ R/G Reduced microglial inflammatory signaling Important in slowing neurodegenerative progression in models.
4 BDNF / CREB signaling ↑ G Synaptic plasticity enhancement Linked to improved memory acquisition in animal and human cognitive studies.
5 Aβ aggregation / toxicity ↓ (preclinical) G Reduced amyloid-associated damage Shown in animal and cell models; human biomarker confirmation limited.
6 Cholinergic signaling ↑ tone (context-dependent) R/G Improved neurotransmission Modest acetylcholinesterase modulation and increased acetylcholine availability reported.
7 Mitochondrial function ↑ R/G Improved bioenergetic resilience Often secondary to reduced ROS and inflammation.
8 Ca²⁺ homeostasis ↔ / stabilized P/R Excitotoxic buffering Indirect stabilization through antioxidant and mitochondrial support.
9 Clinical Translation Constraint ↓ (constraint) — Modest effect size Benefits typically require ≥8–12 weeks; magnitude modest; not disease-modifying therapy.

TSF legend:
P: 0–30 min (direct antioxidant interactions)
R: 30 min–3 hr (acute signaling modulation)
G: >3 hr (gene regulation, synaptic adaptation)
Scientific Papers found: Click to Expand⟱
5475- BM,    https://pmc.ncbi.nlm.nih.gov/articles/PMC6070819/
- in-vitro, Colon, HT29 - in-vitro, Colon, SW48 - in-vitro, Colon, SW-620 - in-vitro, CRC, HCT116
AQPs↓, TumCG↓, TumCCA↓, Apoptosis↑, eff↝,
5486- BM,    Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagy
- in-vivo, Arthritis, NA
*AQPs↓, TumCP↓, Apoptosis↑,
5485- BM,    Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis
- Review, AD, NA
*memory↑,
5484- BM,    The Neurocognitive Effects of Bacopa monnieri and Cognitive Training on Markers of Brain Microstructure in Healthy Older Adults
- in-vivo, AD, NA
*memory↓, *other?,
5483- BM,    The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review
- Review, AD, NA
*cognitive↑, *neuroP↑, *PI3K↑, *Akt↑, *GSK‐3β↓, *tau↓, *ROS↓, *MMP3↓, *Casp1↓, *Casp3↓, *NF-kB↓, *TNF-α↓, *IL6↓,
5482- BM,    Bacopa monnieri protects SH-SY5Y cells against tert-Butyl hydroperoxide-induced cell death via the ERK and PI3K pathways
- in-vitro, Nor, NA
*neuroP↑, *ERK↑, *Akt↑, *MAPK↑, *PI3K↑, *Inflam↓, antiOx↑,
5481- BM,    Therapeutic potential of Bacopa monnieri extracts against hepatocellular carcinoma through in-vitro and computational studies
- in-vitro, HCC, HepG2
tumCV↓, Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, lipid-P↓,
5480- BM,    Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
- Human, Nor, NA
P450↓, CYP3A4↓, CYP2C9↓,
5479- BM,    Importance of high-quality evidence regarding the use of Bacopa monnieri in dementia
- Review, AD, NA
other↝,
5478- BM,    A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment
- Review, AD, NA
*cognitive∅,
5477- BM,    The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis.
- in-vitro, Var, NA
AQPs↓, tumCV↓, Apoptosis↑, TumCMig↓,
5476- BM,    In Vitro Synergistic Inhibition of HT-29 Proliferation and 2H-11 and HUVEC Tubulogenesis by Bacopaside I and II Is Associated with Ca2+ Flux and Loss of Plasma Membrane Integrity
- vitro+vivo, CRC, HT29
TumCD↑, TumCMig↓, Ca+2↑,
3690- BM,    Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer's Disease
- Review, AD, NA
*ROS↓, *5LO↓, *lipid-P↓, *GPx↑, *IronCh↑, *neuroP↑, *AChE↓, *memory↑, *toxicity↓, *SOD↑, *Catalase↑, *cognitive↑, *ChAT↑, *Ach↑, *BP↓,
5474- BM,    Pharmacological attributes of Bacopa monnieri extract: Current updates and clinical manifestation
*memory↑, *neuroP↑, *cognitive↑, *hepatoP↑, *antiOx↑, *AntiDiabetic↑, *fatigue↓, *GSK‐3β↓, *PI3K↑, *Akt↑, *tau↓, *ROS↓, *Inflam↓,
5473- BM,    Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability
- in-vivo, AD, NA - in-vivo, Park, NA
*neuroP↑, *toxicity∅, *AChE↓, *ROS↓, *antiOx↑, *lipid-P↓, *cognitive↑, *memory↑, *Dose↝, *BioAv↓, *TumCCA↑, *BBB↝,
4277- BM,    Reversion of BDNF, Akt and CREB in Hippocampus of Chronic Unpredictable Stress Induced Rats: Effects of Phytochemical, Bacopa Monnieri
- in-vivo, NA, NA
*BDNF↑, *p‑CREB↑,
3698- BM,    Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain
- in-vivo, AD, NA
*lipid-P↓, *ROS↓, *neuroP↑,
3697- BM,    Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies
- Review, AD, NA
*ROS↓, *cognitive↑, *memory↑, *BBB↑, *P-gp↓, *CYP3A2↓,
3696- BM,    Discovery of Molecular Networks of Neuroprotection Conferred by Brahmi Extract in Aβ42-Induced Toxicity Model of Drosophila melanogaster Using a Quantitative Proteomic Approach
- in-vivo, NA, NA
*neuroP↑, *memory↑,
3695- BM,    Bacopa monnieri (L.) wettst. Extract protects against glutamate toxicity and increases the longevity of Caenorhabditis elegans
- in-vitro, AD, HT22
*OS↑, *mt-ROS↓, *ROS↓, *neuroP↑, *ER Stress↓,
3694- BM,    Use of Bacopa monnieri in the Treatment of Dementia Due to Alzheimer Disease: Systematic Review of Randomized Controlled Trials
- Review, AD, NA
*cognitive∅, *other↑,
3693- BM,    Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action
- in-vivo, AD, NA
*cognitive↑, *Aβ↓, *BACE↓, *Inflam↓, *ROS↓, *antiOx↑,
3692- BM,    Brahmi (Bacopa monnieri): An ayurvedic herb against the Alzheimer's disease
- Review, AD, NA
*neuroP↑, *ROS↓, *Inflam↓, *Aβ↓, *cognitive↑,
3691- BM,    Effects of a Standardized Bacopa monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial
- Study, Nor, NA
*cognitive↑, *memory↑, *BP∅,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 24

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   lipid-P↓, 1,  

Core Metabolism/Glycolysis ⓘ

CYP3A4↓, 1,  

Cell Death ⓘ

Apoptosis↑, 4,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,   tumCV↓, 2,  

Cell Cycle & Senescence ⓘ

TumCCA↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

Ca+2↑, 1,   MMP2↓, 1,   MMP9↓, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumCP↓, 2,  

Barriers & Transport ⓘ

AQPs↓, 2,  

Drug Metabolism & Resistance ⓘ

CYP2C9↓, 1,   eff↝, 1,   P450↓, 1,  
Total Targets: 19

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

fatigue↓, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 1,   GPx↑, 1,   lipid-P↓, 3,   ROS↓, 9,   mt-ROS↓, 1,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Core Metabolism/Glycolysis ⓘ

p‑CREB↑, 1,   CYP3A2↓, 1,  

Cell Death ⓘ

Akt↑, 3,   Casp1↓, 1,   Casp3↓, 1,   MAPK↑, 1,  

Transcription & Epigenetics ⓘ

Ach↑, 1,   other?, 1,   other↑, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   GSK‐3β↓, 2,   PI3K↑, 3,  

Migration ⓘ

5LO↓, 1,   MMP3↓, 1,  

Barriers & Transport ⓘ

AQPs↓, 1,   BBB↑, 1,   BBB↝, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL6↓, 1,   Inflam↓, 4,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BDNF↑, 1,   ChAT↑, 1,   tau↓, 2,  

Protein Aggregation ⓘ

Aβ↓, 2,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   Dose↝, 1,  

Clinical Biomarkers ⓘ

BP↓, 1,   BP∅, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cognitive↑, 8,   cognitive∅, 2,   hepatoP↑, 1,   memory↓, 1,   memory↑, 7,   neuroP↑, 9,   OS↑, 1,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 54

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:339  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page